Given the critical roles of TAK1, NF-κB, and EGFR signaling in promoting tumor cell survival and therapy resistance, a deeper understanding of how DHC modulates these pathways could reveal novel strategies for cervical cancer treatment. Here, EGFR is linked to cervical carcinoma.